1. |
Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med, 2014, 35(2): 239-248.
|
2. |
Kawasumi H, Gono T, Kawaguchi Y, et al. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med, 2015, 9(Suppl 1): 9-17.
|
3. |
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis Registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis, 2018, 77(1): 30-39.
|
4. |
Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med, 2010, 49(5): 361-369.
|
5. |
de Souza FHC, de Araújo DB, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol, 2019, 59(1): 6.
|
6. |
Shappley CL, Paik JJ, Saketkoo LA. Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications. Curr Treatm Opt Rheumatol, 2019, 5(1): 56-83.
|
7. |
Shimojima Y, Ishii W, Matsuda M, et al. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol, 2017, 23(2): 87-93.
|
8. |
Ge Y, Peng Q, Zhang S, et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol, 2015, 34(1): 99-105.
|
9. |
Nakashima R, Mimori T. Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi, 2013, 36(2): 71-76.
|
10. |
Nagappa M, Taly AB, Sinha S, et al. Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis, 2013, 14(4): 161-168.
|
11. |
Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol, 2016, 30(1): 149-168.
|
12. |
Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol, 2015, 11(11): 1265-1275.
|
13. |
Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev, 2015, 24(136): 216-238.
|
14. |
Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol, 2012, 24(6): 635-641.
|
15. |
Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol, 2013, 40(5): 640-646.
|
16. |
Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med, 2013, 107(6): 890-896.
|
17. |
Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int, 2016, 36(1): 125-131.
|
18. |
Barba T, Fort R, Cottin V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev, 2019, 18(2): 113-122.
|
19. |
Nagasaka K, Harigai M, Tateishi M, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol, 2003, 13(3): 231-238.
|
20. |
Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol, 2013, 40(4): 484-492.
|
21. |
Kurita T, Yasuda S, Amengual O, et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus, 2015, 24(1): 3-9.
|
22. |
Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther, 2016, 36(36): 46-52.
|
23. |
Ge Y, Zhou H, Shi J, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol, 2015, 34(12): 2097-2103.
|
24. |
Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford), 2015, 54(8): 1420-1428.
|
25. |
Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology, 2014, 19(3): 353-359.
|
26. |
Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol, 2016, 43(8): 1566-1574.
|
27. |
Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep, 2016, 6: 33226.
|
28. |
施善芬, 黎良达, 潘翠萍, 等. 伊马替尼治疗多发性肌炎/皮肌炎合并间质性肺炎患者的疗效分析. 现代实用医学, 2017, 29(8): 994-996.
|
29. |
Hallowell RW, Amariei D, Danoff SK. Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. Ann Am Thorac Soc, 2016, 13(10): 1682-1688.
|
30. |
Giannini M, Fiorella ML, Tampoia M, et al. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology (Oxford), 2020: keaa443.
|
31. |
Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung and Heart-Lung Transplantation Report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant, 2017, 36(10): 1047-1059.
|
32. |
Ameye H, Ruttens D, Benveniste O, et al. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc, 2014, 46(9): 3147-3153.
|
33. |
Betteridge Z, Mchugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2016, 280(1): 8-23.
|
34. |
胡译丹, 刘钢, 谢其冰. 特发性炎性肌病相关的间质性肺疾病. 华西医学, 2018, 33(12): 1544-1548.
|
35. |
Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev, 2012, 12(2): 210-217.
|
36. |
Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 2013, 8(4): e60442.
|
37. |
Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol, 2018, 14(5): 279-289.
|
38. |
So H, Ip RW, Wong VT, et al. Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations. Int J Rheum Dis, 2018, 21(5): 1076-1081.
|
39. |
王怡, 李颖, 李升锦. 抗 MDA5 抗体对成年及幼年型皮肌炎合并间质性肺病诊断效能的 meta 分析. 临床检验杂志, 2018, 36(1): 46-52.
|
40. |
Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol, 2017, 177(5): 1442-1446.
|
41. |
Watanabe R, Ishii T, Araki K, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol, 2016, 26: 465-466.
|
42. |
Hengstman GJ, Ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis, 2006, 65(12): 1635-1638.
|
43. |
Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J, 2003, 22(2): 245-250.
|
44. |
Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 2015, 10: 61.
|
45. |
Garcia-Rosell M, Moore S, Pattanaik D, et al. Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG). J Clin Rheumatol, 2013, 19(4): 214-217.
|
46. |
Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry, 2016, 87(10): 1038-1044.
|